Nemaura Medical Appoints Dr. Arash Ghadar as Chief Operating Officer
January 10 2022 - 8:00AM
Nemaura Medical, Inc. (Nasdaq: NMRD)(“Nemaura” or the “Company”), a
medical technology company focused on developing and
commercializing non-invasive wearable diagnostic devices and
supporting personalized lifestyle coaching programs, announces the
appointment of Dr. Arash (Ash) Ghadar as Chief Operating Officer.
“Ash will play an important role at Nemaura as
we begin to scale up our manufacturing and distribution operations.
He brings over 20 years of product development, management and
leadership experience spanning both business and technical
disciplines. His main area of expertise is in the medical devices
sector, and primarily within a contract design and manufacturing
setting, that will be a true asset for the Company during the
commercialization phase of our growth,” commented CEO Dr. Faz
Chowdhury.
Prior to joining Nemaura, Dr. Ghadar spent a
decade as the Technical Director of Datalink Electronics (Datalink)
in Loughborough, England where he managed the design team as an
autonomous entity within Datalink. He was responsible for
management of the day-to-day operations, business planning, legal
affairs, finance, sales, and business development of the design
team. In this role, he also oversaw numerous technical projects for
healthcare and industrial customers that included product
development lifecycle, feasibility studies, design, development,
prototyping, validation, certification, quality management, and
volume manufacturing.
Dr. Ghadar is also currently a non-executive
director at Medilink Midlands, the Midlands (England) Life Sciences
industry association with a vision to stimulate the growth of the
Midlands life science sector. He has a BSc Degree and Masters in
Electronics and Control Systems Engineering, earning a First Class
degree and Distinction, respectively. He also has a Ph.D. in
Biosensors from the University of Warwick (U.K.).
“I am delighted to join Nemaura, a company with
a world-class ambition to transform people’s lives. I very much
look forward to working with management and the wider team to
successfully commercialize the transformational line of
non-invasive products the Company is developing, beginning with our
continuous glucose monitoring devices and sensors for patients with
diabetes,” said Dr. Ghadar.
About Nemaura Medical,
Inc.
Nemaura Medical Inc. is a medical technology
company developing and commercializing non-invasive wearable
diagnostic devices. The company is currently commercializing
sugarBEAT® and proBEAT™. sugarBEAT®, a CE mark approved Class IIb
medical device, is a non-invasive and flexible continuous glucose
monitor (CGM) providing actionable insights derived from real time
glucose measurements and daily glucose trend data, which may help
people with diabetes and pre-diabetes to better manage, reverse,
and prevent the onset of diabetes. Nemaura has submitted a PMA
(Premarket Approval Application) for sugarBEAT® to the U.S. FDA.
proBEAT™ combines non-invasive glucose data processed using
artificial intelligence and a digital healthcare subscription
service and has been launched in the U.S. as a general wellness
product as part of its BEAT®diabetes program.
The Company sits at the intersection of the
global Type 2 diabetes market that is expected to reach nearly $59
billion by 2025, the $50+ billion pre-diabetic market, and the
wearable health-tech sector for weight loss and wellness
applications that is estimated to reach $60 billion by 2023.
For more information, please visit www.NemauraMedical.com.
Contact:
Jules AbrahamCORE IR917-885-7378julesa@coreir.com
Nemaura Medical (NASDAQ:NMRD)
Historical Stock Chart
From Jun 2024 to Jul 2024
Nemaura Medical (NASDAQ:NMRD)
Historical Stock Chart
From Jul 2023 to Jul 2024